Lhc Group, Inc LHCG
We take great care to ensure that the data presented and summarized in this overview for LHC Group, Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LHCG
View all-
Brinker Capital Investments, LLC24.2KShares$00.08% of portfolio
-
Sarissa Consulting LLC Santa Monica, CA10KShares$01.69% of portfolio
-
Eaton Vance Management Boston, MA7.5KShares$00.0% of portfolio
-
S. Muoio & Co. LLC New York, NY5.5KShares$01.19% of portfolio
-
Walthausen & Co., LLC Malta, NY5.34KShares$00.73% of portfolio
-
Advisor Partners LLC Walnut Creek, CA3.83KShares$00.04% of portfolio
-
Regent Investment Management LLC1.83KShares$00.08% of portfolio
-
Private Capital Group, LLC652Shares$00.08% of portfolio
-
Wipfli Financial Advisors Llc,551Shares$00.01% of portfolio
-
Fieldpoint Private Securities, LLC50Shares$00.0% of portfolio
Latest Institutional Activity in LHCG
Top Purchases
Top Sells
About LHCG
LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. It operates through five segments: Home Health Services, Hospice Services, Home and Community-Based Services, Facility-Based Services, and Healthcare Innovations (HCI). The Home Health Services segment offers skilled nursing, medically oriented social services and physical, occupational, and speech therapy. The Hospice Services segment provides pain and symptom management accompanied by palliative medication, emotional and spiritual support, inpatient and respite care, homemaker services, dietary counseling, family bereavement counseling, and social worker visits. Its Home and Community-Based Services segment offers range of services, such as assistance with grooming, medication reminders, meal preparation, assistance with feeding, light housekeeping, respite care, transportation, and errand. The Facility-Based Services segment treats patients with severe medical conditions who require a high-level of care and frequent monitoring by physicians and other clinical personnel. This segment serves patients suffering from respiratory failure, neuromuscular and cardiac disorders, non-healing wounds, renal disorders, cancer, head and neck injuries, and mental disorders, as well as treats patients diagnosed with musculoskeletal impairments; and operates nursing facilities, family health center, rural health clinic, and physician practice, as well as offers physical therapy services. The HCI segment provides strategic health management services to accountable care organizations. As of December 31, 2021, it operated 557 home health services locations, 170 hospice locations, 136 community-based service locations, 11 long-term acute care hospitals with 12 locations, and 14 HCI locations. The company was founded in 1994 and is based in Lafayette, Louisiana.
Insider Transactions at LHCG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 22
2023
|
W Earl Reed Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
57,848
-100.0%
|
$9,834,160
$170.0 P/Share
|
Feb 22
2023
|
W Earl Reed Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
80,949
-100.0%
|
$13,761,330
$170.0 P/Share
|
Feb 22
2023
|
Jonathan Goldberg Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
6,894
-100.0%
|
$1,171,980
$170.0 P/Share
|
Feb 22
2023
|
Jonathan Goldberg Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
50,578
-100.0%
|
$8,598,260
$170.0 P/Share
|
Feb 22
2023
|
Dale Mackel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,039
-100.0%
|
$3,066,630
$170.0 P/Share
|
Feb 22
2023
|
Bruce D Greenstein Chief Innovation Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,806
-87.2%
|
$3,468,510
$85.0 P/Share
|
Feb 22
2023
|
Teri G. Fontenot Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,700
-100.0%
|
$1,309,000
$170.0 P/Share
|
Feb 22
2023
|
Brent Turner Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,200
-100.0%
|
$2,414,000
$170.0 P/Share
|
Feb 22
2023
|
Ronald T Nixon Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,100
-100.0%
|
$4,607,000
$170.0 P/Share
|
Feb 22
2023
|
Monica F Azare Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,500
-100.0%
|
$5,185,000
$170.0 P/Share
|
Feb 22
2023
|
Clifford S Holtz Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,023
-100.0%
|
$2,043,910
$170.0 P/Share
|
Feb 22
2023
|
Kimberly S Seymour |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,595
-86.11%
|
$475,575
$85.0 P/Share
|
Feb 22
2023
|
Keith G Myers CEO and Chairman |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
604,013
-100.0%
|
$102,682,210
$170.0 P/Share
|
Feb 22
2023
|
Keith G Myers CEO and Chairman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
299,545
-66.49%
|
$25,461,325
$85.0 P/Share
|
Feb 22
2023
|
Joshua L. Proffitt President and COO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
117,443
-80.44%
|
$9,982,655
$85.0 P/Share
|
Feb 22
2023
|
Nicholas Gachassin Iii EVP, General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,860
-100.0%
|
$2,696,200
$170.0 P/Share
|
Feb 22
2023
|
John L Indest Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
30,576
-100.0%
|
$5,197,920
$170.0 P/Share
|
Feb 22
2023
|
John L Indest Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,372
-100.0%
|
$743,240
$170.0 P/Share
|
Feb 13
2023
|
W Earl Reed Iii Director |
BUY
Grant, award, or other acquisition
|
Indirect |
30,000
+50.0%
|
-
|
Feb 13
2023
|
W Earl Reed Iii Director |
SELL
Bona fide gift
|
Direct |
30,000
-27.04%
|
-
|